

Oslo Medicines Initiative (OMI)

Stakeholder engagement



World Health
Organization



Objective

To create a neutral platform on which to build **collaboration between public and private sectors** to improve access to effective, novel, high-priced medicines in the WHO European Region. Three main themes to underpin OMI are **transparency, solidarity and sustainability**.



Methods

- A **collaborative platform** among stakeholders (Member States in the WHO European Region and non-state actors representing industry, the public and payers) was provided to jointly **identify key actions** to improve access, to ensure **discussion and debate** and to identify **potential policy directions** with both a political and a technical line.
- OMI carried out **consultations with all stakeholders**, provided a series of **technical reports and webinars** and published targeted **policy papers**.
- The process consisted of various phases, including a **landscape and needs assessment, building the evidence base, drafting results and dissemination**.



Key
Messages

The OMI has fostered **in-depth dialogue with all relevant stakeholders** on issues of solidarity, transparency and sustainability in the pharmaceutical sector.



Oslo Medicines Initiative (OMI) Research impact



World Health Organization

Final report

“Final Report of the Oslo Medicines Initiative” was published by WHO.

Technical reports

Eight technical reports were commissioned to **analyse the state of the market and policy implementation**, and to **identify policy considerations** that may help Member States and the industry move towards ensuring equitable, sustainable access to effective, novel, high-priced medicines.

Policy brief

“Oslo Medicines Initiative Policy Brief” highlights opportunities for further work to **design and implement policies and supporting tools that promote sustainable access to affordable, effective novel medicines**.

Eurohealth article

The OMI Secretariat was invited to publish “The Oslo Medicines Initiative: Improving Access to High-cost Medicines in Europe” to complement a special issue of Eurohealth.

WHO Regional Committee for Europe

At the 71st session of the Regional Committee for Europe, held virtually in September 2021, the WHO Regional Office for Europe co-hosted a technical briefing with the Government of Norway to provide an **update on progress made with the OMI**, and invited perspectives from Member States, the European Commission, and non-State actors.

Webinar series

Five webinars were held January to February 2022 to further **engage OMI key stakeholder groups**, and to **enable open discussion and knowledge exchange** of emerging findings from the technical reports from diverse perspectives.

European Health Forum Gastein (EHFG)

Since 2020, the OMI has been on the agenda of the **European Health Forum Gastein (EHFG)**, with presentations on various topics.

